Request for Information: 340B Rebate Model Pilot Program Extension
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Issuing agencies
Abstract
The Health Resources and Services Administration (HRSA) is extending the comment period for Request for Information: 340B Rebate Model Pilot Program from 30 days to 60 days. The change will provide stakeholders additional time to submit meaningful comments for HRSA's review in evaluating operational, financial, and potential impacts on access to drugs for patients under a rebate model.
Full Text
<html> <head> <title>Federal Register, Volume 91 Issue 38 (Thursday, February 26, 2026)</title> </head> <body><pre> [Federal Register Volume 91, Number 38 (Thursday, February 26, 2026)] [Notices] [Page 9632] From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>] [FR Doc No: 2026-03838] ----------------------------------------------------------------------- DEPARTMENT OF HEALTH AND HUMAN SERVICES Health Resources and Services Administration Request for Information: 340B Rebate Model Pilot Program Extension AGENCY: Health Resources and Services Administration (HRSA), Department of Health and Human Services. ACTION: Notice of extension for the comment period for the Request for Information: 340B Rebate Model Pilot Program (91 FR 7287). ----------------------------------------------------------------------- SUMMARY: The Health Resources and Services Administration (HRSA) is extending the comment period for Request for Information: 340B Rebate Model Pilot Program from 30 days to 60 days. The change will provide stakeholders additional time to submit meaningful comments for HRSA's review in evaluating operational, financial, and potential impacts on access to drugs for patients under a rebate model. DATES: Comments on this notice should be received no later than April 20, 2026. FOR FURTHER INFORMATION CONTACT: Chantelle Britton, Director, Office of Pharmacy Affairs (OPA), Office of Special Health Initiatives, HRSA, 5600 Fishers Lane, Mail Stop 10W29, Rockville, MD 20857; email: <a href="/cdn-cgi/l/email-protection#596a6d691b292b303a30373e19312b2a38773e362f"><span class="__cf_email__" data-cfemail="fac9cecab88a88939993949dba9288899bd49d958c">[email protected]</span></a>; telephone: 301-594-4353. SUPPLEMENTARY INFORMATION: None. Thomas J. Engels, Administrator. [FR Doc. 2026-03838 Filed 2-25-26; 8:45 am] BILLING CODE P </pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body> </html>
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.